Streetbeat News

Revenues

TSQ

Townsquare Media projects its FY24 revenue to be in the range of $440M-$460M, which is below the estimated $465.2M. The company also forecasts its FY24 adjusted EBITDA to be between $100M-$110M.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 10:14 am

TSQ

Townsquare Media anticipates Q1 revenue to be in the range of $98.5M-$100M, falling short of the expected $103.02M. The company also forecasts its Q1 adjusted EBITDA to be between $17.5M-$18.5M.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 10:12 am

ADBE

CLSK

COIN

MARA

MSTR

PD

RIOT

SMAR

ULTA

In Friday's pre-market session, Adobe Inc. (ADBE) shares fell sharply after reporting Q1 results with weak Q2 revenue guidance. Other stocks like Smartsheet Inc. (SMAR), PagerDuty, Inc. (PD), MicroStrategy Incorporated (MSTR), Ulta Beauty, Inc. (ULTA), CleanSpark, Inc. (CLSK), Coinbase Global, Inc. (COIN), Marathon Digital Holdings, Inc. (MARA), and Riot Platforms, Inc. (RIOT) also recorded losses, mainly due to disappointing financial results or a pullback in Bitcoin prices.

Portfolio Pulse from Avi Kapoor

March 15, 2024 | 9:31 am

EH

EHang Holdings anticipates a significant revenue increase for Q1 2024, expecting around RMB58.0 million, which marks a 160% growth compared to the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 8:08 am

EWQ

France's Consumer Price Index (CPI) for February showed a monthly increase of 0.8%, aligning with the estimated 0.8% and marking a significant change from the -0.3% observed in the prior month.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 7:49 am

BMY

Bristol Myers Squibb's Breyanzi has been approved by the U.S. FDA as the first and only CAR T cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval marks a significant advancement in treatment options for patients with these conditions, offering a one-time infusion that has shown deep and durable responses. In the TRANSCEND CLL 004 trial, 20% of patients achieved a complete response, with the median duration of response not yet reached. Breyanzi is also approved for relapsed or refractory large B-cell lymphoma, expanding its potential patient base.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 5:28 am

TSNDF

TerrAscend Corp. (OTCQX:TSNDF) reported a 28% year-over-year revenue increase for 2023, totaling $317.3 million, driven by sales in Maryland and New Jersey. Q4 revenue rose 25.5% to $86.6 million. Despite a Q4 GAAP net loss of $41.8 million due to non-cash impairment charges, the company achieved positive cash flow for the first time in its history, with $31.1 million from continuing operations and $23.4 million in free cash flow. The company's gross profit margin improved significantly, reaching 50.3% for the year. TerrAscend aims for expansion in 2024, leveraging its strong operational foundation.

Portfolio Pulse from Maureen Meehan

March 15, 2024 | 2:13 am

RDW

Redwire Corporation projects its 2024 revenues to reach $300 million, surpassing the estimated $278.832 million. This forecast suggests a positive outlook for the company's financial growth.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 9:32 pm

MNTK

Montauk Renewables projects its 2024 RNG revenues to be between $195M-$215M, with RNG production volumes expected between 5.8 and 6.1 million MMBtu. Renewable Electricity revenues are anticipated to be between $18.0 and $19.0 million, with production volumes between 190 and 200 thousand MWh.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 9:07 pm